Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statins may decrease skeletal-related events in breast cancer patients with bone metastases.

Murat Dincer1, Nilufer Bulut, Hakan Harputluoglu

  • 1Department of Medical Oncology, Hacettepe University Institute of Oncology, Sihhiye, Ankara 06100, Turkey.

Medical Hypotheses
|July 18, 2006
PubMed
Summary

Statins, commonly used for lowering cholesterol, may help prevent skeletal complications in breast cancer patients with bone metastases. By inhibiting the same pathway as bisphosphonates, statins could reduce osteoclast activity and related skeletal events.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigation of the effects of radiotherapy and chemotherapy on brain volume in cancer patients: brain tumor study.

Journal of neuro-oncology·2026
Same author

Multilocus inherited neoplasia allele syndrome (MINAS) in a Turkish cohort: molecular insights and clinical relevance for precision oncology.

Frontiers in pharmacology·2026
Same author

Real‑world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group retrospective study.

Molecular and clinical oncology·2025
Same author

Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes.

Cancers·2024
Same author

Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10).

Urologic oncology·2024
Same author

Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2024

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Biology

Background:

  • Bone metastasis is a common complication in breast cancer patients, leading to skeletal-related events (SREs) such as pain, fractures, and spinal cord compression.
  • Bisphosphonates are the standard treatment for reducing SREs by inhibiting osteoclast activity via the mevalonate pathway.
  • The mevalonate pathway is also crucial for cholesterol synthesis, presenting a potential therapeutic target for other drug classes.

Purpose of the Study:

  • To explore the potential of statins, cholesterol-lowering drugs, in reducing skeletal-related events in breast cancer patients with bone metastases.
  • To investigate if statins can inhibit osteoclast activity through the shared mevalonate pathway, similar to bisphosphonates.

Main Methods:

  • This study reviews the pharmacological action of statins and bisphosphonates on the mevalonate pathway.

Related Experiment Videos

  • It analyzes existing literature on the effects of statins on bone metabolism and osteoclast function.
  • The potential clinical application of statins in managing bone metastases from breast cancer is discussed.

    • Main Results:

    • Statins inhibit the mevalonate pathway, a mechanism shared with bisphosphonates.
    • This inhibition is expected to reduce osteoclast activity, thereby potentially mitigating SREs.
    • Statins' cholesterol-lowering properties suggest a dual benefit in cardiovascular health and bone metastasis management.

    Conclusions:

    • Statins represent a promising therapeutic strategy for reducing skeletal-related events in breast cancer patients with bone metastases.
    • Further clinical studies are warranted to confirm the efficacy and safety of statins in this patient population.
    • Targeting the mevalonate pathway with statins could offer a novel approach to managing bone metastases and improving patient outcomes.